BRISTOL-MYERS SQUIBB COMPANY Total Long-Term Debt
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Total Long-Term Debt of $42.86 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2026-07-30
- 2026-06-30: Long-term Debt $42.86B.
- 2026-03-31: Long-term Debt $44.14B.
- 2025-12-31: Long-term Debt $44.83B.
- 2025-09-30: Long-term Debt $48.72B.
| Period end | Long-term Debt |
|---|---|
| 2026-06-30 | $42.86B 10-Q · filed 2026-07-30 |
| 2026-03-31 | $44.14B 10-Q · filed 2026-04-30 |
| 2025-12-31 | $44.83B 10-Q · filed 2026-07-30 |
| 2025-09-30 | $48.72B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $48.95B 10-Q · filed 2025-07-31 |
| 2025-03-31 | $49.51B 10-Q · filed 2025-04-24 |
| 2024-12-31 | $49.43B 10-K · filed 2026-02-11 |
| 2024-09-30 | $49.55B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $51.95B 10-Q · filed 2024-07-26 |
| 2024-03-31 | $52.36B 10-Q · filed 2024-04-25 |
| 2023-12-31 | $39.53B 10-K · filed 2025-02-12 |
| 2023-09-30 | $37.01B 10-Q · filed 2023-10-26 |
| 2023-06-30 | $37.07B 10-Q · filed 2023-07-27 |
| 2023-03-31 | $37.33B 10-Q · filed 2023-04-27 |
| 2022-12-31 | $38.95B 10-K · filed 2024-02-13 |
| 2022-09-30 | $38.87B 10-Q · filed 2022-10-26 |
| 2022-06-30 | $41.75B 10-Q · filed 2022-07-27 |
| 2022-03-31 | $44.75B 10-Q · filed 2022-04-29 |
| 2021-12-31 | $44.37B 10-K · filed 2023-02-14 |
| 2021-09-30 | $44.45B 10-Q · filed 2021-10-27 |
| 2021-06-30 | $45.00B 10-Q · filed 2021-07-28 |
| 2021-03-31 | $46.01B 10-Q · filed 2021-04-29 |
| 2020-12-31 | $50.34B 10-K · filed 2022-02-09 |
| 2020-09-30 | $44.61B 10-K · filed 2021-02-10 |
| 2020-06-30 | $46.11B 10-K · filed 2021-02-10 |
| 2020-03-31 | $46.10B 10-K · filed 2021-02-10 |
| 2019-12-31 | $46.15B 10-K · filed 2021-02-10 |
| 2019-09-30 | $24.39B 10-K · filed 2021-02-10 |
| 2019-06-30 | $24.43B 10-K · filed 2021-02-10 |
| 2019-03-31 | $5.63B 10-K · filed 2021-02-10 |
| 2018-12-31 | $6.89B 10-K · filed 2020-02-24 |
| 2018-09-30 | $5.69B 10-K · filed 2020-02-24 |
| 2018-06-30 | $5.67B 10-K · filed 2020-02-24 |
| 2018-03-31 | $5.78B 10-K · filed 2020-02-24 |
| 2017-12-31 | $6.97B 10-K · filed 2019-02-25 |
| 2017-09-30 | $6.98B 10-K · filed 2019-02-25 |
| 2017-06-30 | $6.91B 10-K · filed 2019-02-25 |
| 2017-03-31 | $7.24B 10-K · filed 2019-02-25 |
| 2014-09-30 | $7.27B 10-K · filed 2015-02-13 |
| 2014-06-30 | $7.37B 10-K · filed 2015-02-13 |
| 2014-03-31 | $7.37B 10-K · filed 2015-02-13 |
| 2013-12-31 | $7.98B 10-K · filed 2014-02-14 |
| 2013-09-30 | $6.56B 10-K · filed 2015-02-13 |
| 2013-06-30 | $7.12B 10-K · filed 2015-02-13 |
| 2013-03-31 | $7.18B 10-K · filed 2015-02-13 |
| 2012-12-31 | $7.23B 10-K · filed 2014-02-14 |
| 2012-09-30 | $7.23B 10-K · filed 2014-02-14 |
| 2012-06-30 | $5.21B 10-K · filed 2014-02-14 |
| 2012-03-31 | $5.27B 10-K · filed 2014-02-14 |
| 2011-12-31 | $5.38B 10-K · filed 2013-02-15 |
| 2011-09-30 | $5.44B 10-K · filed 2013-02-15 |
| 2011-06-30 | $5.33B 10-K · filed 2013-02-15 |
| 2011-03-31 | $5.28B 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |